BACKGROUND: Central nervous system (CNS) tumors are the second most common childhood malignancy. The French National Registry of Childhood Solid Tumors (NRCST) makes it possible to describe this variety of distinct tumor types and to provide incidence and survival data in France on a nationwide basis. METHODS: All children aged 0-14 years, who were registered with a primary CNS tumor in the NRCST of France between 2000 and 2008, were identified. Tumors were classified according to the International Classification of Childhood Cancer, third edition. RESULTS: Approximately 57% of pediatric CNS tumors were gliomas, with astrocytomas of the pilocytic type predominating. Distributions of subtypes by age showed that primitive neuroectodermal tumors and ependymomas mainly occurred in children aged <5 years. The mean annual incidence rate of CNS tumors was 39 per million. No statistically significant change in time trends of incidence rate was observed during 2000-2008. For all tumors combined, overall survival was 84.8% (95% CI, 83.7%-85.9%) at 1 year and 72.9% (95% CI, 71.5%-74.3%) at 5 years. Survival time trends were studied in a multivariate analysis observing a reduction in the risk of death in periods of diagnosis 2003-2005 (HR = 0.8; 95% CI, 0.7–0.9) and 2006-2008 (HR = 0.7; 95% CI, 0.6-0.9) compared with 2000-2002. CONCLUSIONS: The stable incidence rates during the last 10 years could indicate that major changes in environmental risk factors are unlikely, but the ongoing need for population-based surveillance remains relevant. Results indicate a positive trend in the survival probability still persistent in the 2000s.
BACKGROUND:Central nervous system (CNS) tumors are the second most common childhood malignancy. The French National Registry of Childhood Solid Tumors (NRCST) makes it possible to describe this variety of distinct tumor types and to provide incidence and survival data in France on a nationwide basis. METHODS: All children aged 0-14 years, who were registered with a primary CNS tumor in the NRCST of France between 2000 and 2008, were identified. Tumors were classified according to the International Classification of Childhood Cancer, third edition. RESULTS: Approximately 57% of pediatric CNS tumors were gliomas, with astrocytomas of the pilocytic type predominating. Distributions of subtypes by age showed that primitive neuroectodermal tumors and ependymomas mainly occurred in children aged <5 years. The mean annual incidence rate of CNS tumors was 39 per million. No statistically significant change in time trends of incidence rate was observed during 2000-2008. For all tumors combined, overall survival was 84.8% (95% CI, 83.7%-85.9%) at 1 year and 72.9% (95% CI, 71.5%-74.3%) at 5 years. Survival time trends were studied in a multivariate analysis observing a reduction in the risk of death in periods of diagnosis 2003-2005 (HR = 0.8; 95% CI, 0.7–0.9) and 2006-2008 (HR = 0.7; 95% CI, 0.6-0.9) compared with 2000-2002. CONCLUSIONS: The stable incidence rates during the last 10 years could indicate that major changes in environmental risk factors are unlikely, but the ongoing need for population-based surveillance remains relevant. Results indicate a positive trend in the survival probability still persistent in the 2000s.
Authors: P Chastagner; C Kalifa; F Doz; E Bouffet; J C Gentet; M M Ruchoux; S Bracard; E Desandes; D Frappaz Journal: Pediatr Blood Cancer Date: 2007-11 Impact factor: 3.167
Authors: Maryam Fouladi; Daniel L Hunt; Ian F Pollack; Gregor Dueckers; Peter C Burger; Laurence E Becker; Allen J Yates; Floyd H Gilles; Richard L Davis; James M Boyett; Jonathan L Finlay Journal: Cancer Date: 2003-09-15 Impact factor: 6.860
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: E Story; D L Johnston; U Bartels; A S Carret; B Crooks; D D Eisenstat; C Fryer; L Lafay-Cousin; V Larouche; B Wilson; S Zelcer; M Silva; J Brossard; E Bouffet; D L Keene Journal: J Neurooncol Date: 2017-05-16 Impact factor: 4.130
Authors: S Rivas-Vilela; J Rubió-Casadevall; A Fàbrega-Ribas; C Joly-Torta; L Vilardell; R Marcos-Gragera Journal: Clin Transl Oncol Date: 2019-02-02 Impact factor: 3.405
Authors: Teresa de Rojas; Francisco Bautista; Miguel Flores; Lucía Igual; Raquel Rubio; Eduardo Bardón; Lucía Navarro; Laura Murillo; Raquel Hladun; Adela Cañete; Miguel Garcia-Ariza; Carmen Garrido; Ana Fernández-Teijeiro; Eduardo Quiroga; Carlota Calvo; Anna Llort; Inmaculada de Prada; Luis Madero; Ofelia Cruz; Lucas Moreno Journal: J Neurooncol Date: 2017-12-16 Impact factor: 4.130
Authors: Emma A Lim; César A P F Alves; Stefania Picariello; Kristian Aquilina; Sotirios Bisdas; Ulrike Loebel; Kshitij Mankad; Felice D'Arco Journal: Childs Nerv Syst Date: 2021-09-16 Impact factor: 1.532
Authors: Eduardo Javier Barragán-Pérez; Carlos Enrique Altamirano-Vergara; Daniel Eduardo Alvarez-Amado; Juan Carlos García-Beristain; Fernando Chico-Ponce-de-León; Vicente González-Carranza; Luis Juárez-Villegas; Chiharu Murata Journal: Pathol Oncol Res Date: 2020-07-13 Impact factor: 2.874
Authors: Eva Steliarova-Foucher; Miranda M Fidler; Murielle Colombet; Brigitte Lacour; Peter Kaatsch; Marion Piñeros; Isabelle Soerjomataram; Freddie Bray; Jan Willem Coebergh; Rafael Peris-Bonet; Charles A Stiller Journal: Lancet Oncol Date: 2018-08-08 Impact factor: 41.316